Growth Factors Can Cooperate to Promote Tumorigenesis
Introduction
Tumorigenesis, the process by which normal cells transform into cancer cells, is a multifaceted and complex event influenced by various internal and external factors. Among these, growth factors play a pivotal role in cellular communication and regulation, often being the critical elements that can tip the balance towards cancer development when dysregulated. This article delves into how growth factors, through their intricate network and interactions, can cooperate to promote tumorigenesis, highlighting the mechanisms behind their action and the implications for cancer therapy.
The Role of Growth Factors in Cell Regulation
Growth factors are proteins that bind to specific receptors on the surface of cells, triggering a cascade of signaling pathways that regulate cell growth, differentiation, survival, and migration. They are essential for normal development and tissue maintenance. However, when their regulation is disrupted, it can lead to uncontrolled cell proliferation and cancer.
Key Growth Factors in Tumorigenesis
- Epidermal Growth Factor (EGF): Promotes cell growth and differentiation. Its overexpression or the overactivity of its receptor, EGFR, is observed in various cancers.
2. Fibroblast Growth Factors (FGFs): Involved in angiogenesis, the process by which new blood vessels form, providing tumors with nutrients and oxygen.
Mechanisms of Cooperation Among Growth Factors
Growth factors do not act in isolation but interact within a complex network that can lead to synergistic effects on tumorigenesis. The cooperation between different growth factors can occur through several mechanisms:
Cross-Talk Between Signaling Pathways
Modulation of the Tumor Microenvironment
Induction of Epithelial-Mesenchymal Transition (EMT)
Emerging Research Areas in Growth Factor Signaling and Tumorigenesis
Potential Therapeutic Targets
Table 1: Cooperation of Growth Factors in Tumorigenesis
Growth Factor | Role in Tumorigenesis | Mechanism of Cooperation |
EGF | Cell proliferation and differentiation | Amplifies oncogenic signals through cross-talk with other pathways |
FGF | Angiogenesis and cell survival | Collaborates with VEGF to enhance angiogenesis |
VEGF | Angiogenesis | Works with FGF to supply the tumor with nutrients and oxygen |
TGF-β | Tumor progression and immunosuppression | Induces EMT and suppresses immune response, facilitating metastasis |
Implications for Cancer Therapy
Conclusion
References
- Hanahan, D. and Weinberg, R.A., 2011. Hallmarks of cancer: The next generation. Cell, 144(5), pp.646-674.
- Lemmon, M.A. and Schlessinger, J., 2010. Cell signaling by receptor tyrosine kinases. Cell, 141(7), pp.1117-1134.
- Carmeliet, P. and Jain, R.K., 2011. Molecular mechanisms and clinical applications of angiogenesis. Nature, 473(7347), pp.298-307.
- Massagué, J., 2008. TGFβ in Cancer. Cell, 134(2), pp.215-230.
- Weis, S.M. and Cheresh, D.A., 2011. Tumor angiogenesis: Molecular pathways and therapeutic targets. Nature Medicine, 17(11), pp.1359-1370.
- Thiery, J.P., Acloque, H., Huang, R.Y.J., and Nieto, M.A., 2009. Epithelial-mesenchymal transitions in development and disease. Cell, 139(5), pp.871-890.
- Prenzel, N., Fischer, O.M., Streit, S., Hart, S., and Ullrich, A., 2001. The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. Endocrine-Related Cancer, 8(1), pp.11-31.
- Ferrara, N., Hillan, K.J., Gerber, H.P., and Novotny, W., 2004. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nature Reviews Drug Discovery, 3(5), pp.391-400.
- O'Brien, J., Hayder, H., Zayed, Y., and Peng, C., 2018. Overview of MicroRNA biogenesis, mechanisms of actions, and circulation. Frontiers in Endocrinology, 9, p.402.
- Batlle, E. and Clevers, H., 2017. Cancer stem cells revisited. The New England Journal of Medicine, 377(13), pp.1250-1261.
- Suda, K., Tomizawa, K., and Fujii, M., 2017. Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib. Journal of Thoracic Oncology, 6(7), pp.1152-1161.
- Engelman, J.A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J.O., Lindeman, N., Gale, C.M., Zhao, X., Christensen, J., Kosaka, T., Holmes, A.J., Rogers, A.M., Cappuzzo, F., Mok, T., Lee, C., Johnson, B.E., Cantley, L.C. and Janne, P.A., 2007. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science, 316(5827), pp.1039-1043.
- Polivka, J. Jr., and Janku, F., 2014. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway. Pharmacology & Therapeutics, 142(2), pp.164-175.
- Sun, Y., 2010. Tumor microenvironment and cancer therapy resistance. Cancer Letters, 289(2), pp.205-210.
Written by Zainab Riaz
Zainab Riaz completed her Master degree in Zoology from Fatimah Jinnah University in Pakistan and is currently pursuing a Doctor of Philosophy in Zoology at University of Lahore in Pakistan.
Recent Posts
-
TREM2: Exploring Its Role in Tumor-Associated Macrophages and Cancer Immunotherapy
Introduction to TREM2 and Tumor-Associated Macrophages in CancerTREM2 (triggering rece …31st Oct 2024 -
FoxP3: Understanding Regulatory T Cell Control in Tumor Immunity
Introduction to FoxP3 and Regulatory T Cells in CancerFoxP3 (forkhead box P3) is a tra …30th Oct 2024 -
CD155: Breaking Immune Suppression in Tumor Environments
Introduction to CD155 in Cancer ImmunotherapyCD155, also known as Poliovirus Receptor …29th Oct 2024